Story
Eli Lilly Delays FDA Filing for Next-Gen Obesity Drug Retatrutide to Q1 2027

Eli Lilly said Thursday it now plans to file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, a significant delay from its previous timeline targeting this year. The pharmaceutical giant stated it requires additional time to collect and verify manufacturing and quality-control data to meet regulatory standards.
Filing Delayed Despite Strong Trial Results
The revised timeline comes despite the company reporting positive outcomes from two additional Phase 3 trials. The weekly injection demonstrated substantial weight loss and improved blood sugar levels in adults with obesity and related health complications.
Key findings from the 80-week trials include:
- Adults with obesity and Type 2 diabetes lost an average of up to 20.8% of their body weight, or nearly 50 pounds.
- Adults with severe obesity and established cardiovascular disease lost an average of up to 22.6% of their body weight, or 55.8 pounds.
Common side effects were reported as diarrhea, nausea, and constipation, which the company noted are consistent with previous studies and the broader GLP-1 class of drugs.
Market Implications and Competitive Landscape
AdRetatrutide is a critical component of Lilly's strategy to dominate the lucrative weight-loss drug market, following its successful launch of Zepbound. Analysts at TD Cowen previously estimated in a January report that retatrutide could generate annual sales of $3.8 billion by 2030. The delay pushes back the potential timeline for these revenues.
The obesity drug market is intensely competitive, primarily between Eli Lilly and Danish rival Novo Nordisk, which manufactures Wegovy. The competitive pressure was highlighted earlier this week when Novo Nordisk filed a lawsuit against Lilly, alleging false advertising related to the performance of its weight-loss medications.
A Differentiated 'Triple-Agonist' Drug
Unlike existing treatments, retatrutide is a 'triple-agonist' that targets three distinct hormones involved in metabolism: GLP-1, GIP, and glucagon. This mechanism differs from Lilly's own Zepbound (tirzepatide), which targets GLP-1 and GIP, and Novo Nordisk's Wegovy (semaglutide), which mimics only GLP-1.
Kenneth Custer, president of Lilly Cardiometabolic Health, stated that the company believes it has the necessary information to eventually seek global approval for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.